GlassScriptPhysician profile
Kimberly D Collins
NPI 1932203262
$1,899.20
in general payments reported to CMS, 2019-2025
32 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $473 · 2022: $274 · 2023: $396 · 2024: $359 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $276.79 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $250.97 | 2021-2025 | Flumist Quadrivalent, Breztri, Evusheld |
| Novo Nordisk INC | $164.96 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $146.55 | 2021-2025 | Aveir, Freestyle Libre |
| Dexcom, INC. | $90.97 | 2023-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $87.01 | 2022-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $75.68 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $66.64 | 2024-2025 | |
| Abbvie INC. | $62.78 | 2021-2023 | |
| Mylan Specialty L.P. | $54.74 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.15 | 2022 | |
| Pfizer INC. | $45.29 | 2021 | |
| Ironwood Pharmaceuticals, INC | $45.02 | 2024 | |
| Novartis Pharmaceuticals Corporation | $42.01 | 2022-2023 | |
| Boston Scientific Corporation | $41.12 | 2025 | Watchman Access System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.89 | 2021-2022 | |
| Medtronic, INC. | $37.20 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $33.64 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $30.60 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $26.97 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $26.42 | 2022 | |
| Amarin Pharma, INC. | $26.39 | 2021 | |
| Sobi, INC | $25.44 | 2023 | |
| Viatris Specialty LLC | $20.05 | 2025 | Yupelri |
| Ironshore Pharmaceuticals INC. | $18.61 | 2023 | Jornay Pm |
| Lilly USA, LLC | $17.67 | 2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $17.58 | 2022 | |
| Medline Industries LP | $16.88 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.83 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.59 | 2023 | Austedo Xr |
| Exact Sciences Corporation | $13.47 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.